Ionis partner GSK wins US approval for Hibsago to treat chronic hepatitis B

By Public Technologies
  • Ionis Pharmaceuticals partner GSK secured U.S. FDA approval for Hibsago, or bepirovirsen, with antiviral therapy for eligible adults with chronic hepatitis B.
  • Reported Phase 3 results showed a six-month course improved functional cure outcomes versus placebo, allowing some patients to remain off treatment.
  • Use is limited to adults without cirrhosis whose infection is suppressed following at least six months of antiviral therapy.
  • Boxed warnings cover liver flares and potentially life-threatening platelet reductions.
  • GSK licensed bepirovirsen in 2019; the agreement provides additional milestone payments and tiered royalties of 10-12% on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610202120BIZWIRE_USPR_____20261020_BW102530) on October 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.